leadf
logo-loader
NYSE:MTNB

Matinas BioPharma

Receive alerts
Market:
NYSE
Market Cap:
$154.07 m
Price
0.77 USD
Change
-2.00%
52 weeks high
2.48
52 weeks low
0.49

In brief

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors.

In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on Matinas’ proprietary lipid nano-crystal (LNC) platform technology which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable. 

Snapshot

The New Jersey-based company's lead product candidate, MAT9001 is for the treatment of cardiovascular and metabolic conditions